IL6ST and neoplasm: We then evaluated whether BZA treatment reduced tumour burden in vivo by subcutaneously engrafting HT29 sh-co and HT29 sh-gp130 cells into immune-compromised NOD scid gamma (NSG) mice (Fig. 2F).